TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31523680

Group type: EXPERIMENTAL
Intervention: Stabilization training
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Equilibrium training
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 27
Study: 30464398

Group type: EXPERIMENTAL
Intervention: Tongfu powder
Number of subjects: 102

Group type: COMPARATOR
Intervention: Mosapride
Number of subjects: 102
Study: 26999011

Group type: EXPERIMENTAL
Intervention: Exclusive Breast Feeding (EBF)
Number of subjects: 1629
Study: 24786356

Group type: EXPERIMENTAL
Intervention: Evacetrapib monotherapy 30 mg
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Evacetrapib monotherapy 100 mg
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Evacetrapib monotherapy 500 mg
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Evacetrapib 100 mg in combination with atorvastatin 10 mg
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 165
Study: 22430452

Group type: EXPERIMENTAL
Intervention: Nurse-initiated corticosteroids
Number of subjects: 644
Study: 20405165

Group type: EXPERIMENTAL
Intervention: Radioactive iodine (RAI) (n = 24)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Carbimazole (CBZ) (n = 22)
Number of subjects: 46
Study: 18633023

Group type: EXPERIMENTAL
Intervention: Three or more prophylactic antiemetics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Compliance with ASA guidelines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Compliance with ASPAN guidelines
Number of subjects: 0

Group type: COMPARATOR
Intervention: <1 prophylactic antiemetic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall antiemetic administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rescue medication use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate-to-severe nausea
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional interference due to emetic symptoms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complete control (CR and no moderate-severe nausea)
Number of subjects: 0
Study: 15946427

Group type: EXPERIMENTAL
Intervention: halogenated anesthetic/oxygen/N2O mixture
Number of subjects: 50

Group type: COMPARATOR
Intervention: halogenated anesthetic/oxygen/air mixture
Number of subjects: 50
Study: 12594633

Group type: EXPERIMENTAL
Intervention: Tafenoquine 25 mg/week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tafenoquine 50 mg/week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tafenoquine 100 mg/week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tafenoquine 200 mg/week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mefloquine 250 mg/week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11783334

Group type: EXPERIMENTAL
Intervention: Ganrening Granule (GRN)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 400
Study: 8813919

Group type: EXPERIMENTAL
Intervention: Computer-controlled monitoring of bladder pressure (Group B)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Unmonitored patients (Group A)
Number of subjects: 53
Study: 1593461

Group type: EXPERIMENTAL
Intervention: Maintain force task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maintain position task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Local anaesthesia of the radial nerve
Number of subjects: 0
Study: 3939672

Group type: EXPERIMENTAL
Intervention: 60 mg b.i.d. of terfenadine
Number of subjects: 560

Group type: COMPARATOR
Intervention: 4 mg t.i.d. of chlorpheniramine (active control)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 560
Study: 31188704

Group type: EXPERIMENTAL
Intervention: Rest Redistribution (RR) with 30-s intraset rest and 90-s interset rest
Number of subjects: 12

Group type: COMPARATOR
Intervention: Traditional sets with 120-s interset rest
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rest Redistribution (RR)
Number of subjects: 12
Study: 29559697

Group type: EXPERIMENTAL
Intervention: Active fixation (screw) leads
Number of subjects: 326

Group type: COMPARATOR
Intervention: Passive fixation (tine) leads
Number of subjects: 326
Study: 27733098

Group type: EXPERIMENTAL
Intervention: Piezoelectric microdosing (1 × 1.5 μl, 1 × 6 μl, or 2 × 3 μl of phenylephrine 2.5% and tropicamide 1.0%)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Piezoelectric microdosing (2 × 3 μl)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Piezoelectric saline self-delivery
Number of subjects: 102

Group type: COMPARATOR
Intervention: Eyedropper doses of phenylephrine and tropicamide
Number of subjects: 102
Study: 24322433

Group type: EXPERIMENTAL
Intervention: Continuous ultrasound (US) at a frequency of 1 MHz with intensity of 1 W/cm
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound (US) at the same frequency and intensity on 1:4 pulse ratio
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham ultrasound
Number of subjects: 60
Study: 22337156

Group type: EXPERIMENTAL
Intervention: Enhanced format consent documents (printed on 20-pound, cream-colored bond paper and presented in a blue folio)
Number of subjects: 499

Group type: COMPARATOR
Intervention: Standard format consent documents (stapled set of photocopied pages)
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Enhanced format consent documents
Number of subjects: 499

Group type: COMPARATOR
Intervention: Standard format consent documents
Number of subjects: 499
Study: 20430458

Group type: EXPERIMENTAL
Intervention: TRG0 (Pathological complete response)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: TRG1 (Good regression)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: TRG2 (Moderate regression)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: TRG3 (Poor regression)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: TRG0
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: TRG1
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: TRG2
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: TRG3
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: TRG1 vs TRG2 vs TRG3 (persistent disease)
Number of subjects: 131
Study: 18377704

Group type: EXPERIMENTAL
Intervention: Group A (no controlled hypotension)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Group B (controlled hypotension)
Number of subjects: 30
Study: 15782877

Group type: EXPERIMENTAL
Intervention: 48-month reminder letter to have a Pap test (n=60,000)
Number of subjects: 90000

Group type: COMPARATOR
Intervention: No reminder letter (n=30,000)
Number of subjects: 90000
Study: 14744332

Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arthroscopic surgery
Number of subjects: 0
Study: 12034516

Group type: EXPERIMENTAL
Intervention: Oral tibolone 2.5 mg per day
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Cyclic combined regimen of transdermal oestrogen and progestogen
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Intermittent progesterone regimen
Number of subjects: 165
Study: 9471928

Group type: EXPERIMENTAL
Intervention: Carotid arterial intima-media thickness measurement
Number of subjects: 146
Study: 8869019

Group type: EXPERIMENTAL
Intervention: Integrelin (glycoprotein IIb/IIIa receptor inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher doses of integrelin
Number of subjects: 0
Study: 2357919

Group type: EXPERIMENTAL
Intervention: Follow-up intervention (telephone calls and home visit)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard protocol (3-day educational program and review session)
Number of subjects: 60
Study: 388400

Group type: EXPERIMENTAL
Intervention: 250 mg tienilic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 125 mg tienilic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: 50 mg hydrochlorothiazide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: tienilic acid and hydrochlorothiazide
Number of subjects: 0
Study: 6309204

Group type: EXPERIMENTAL
Intervention: suxamethonium 10 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: gallamine 20 mg
Number of subjects: 50
Study: 29415697

Group type: EXPERIMENTAL
Intervention: WhiteTeeth app in addition to care as usual
Number of subjects: 146

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 146
Study: 28116306

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 25122928

Group type: EXPERIMENTAL
Intervention: Predictive model for preeclampsia including placental growth factor, mean arterial pressure, body mass index, consumption of ≥3 pieces of fruit per day, mean uterine artery resistance index
Number of subjects: 5623

Group type: EXPERIMENTAL
Intervention: Predictive model for early-onset preeclampsia including angiogenin/placental growth factor ratio, mean arterial pressure, any pregnancy loss <10 weeks, mean uterine artery resistance index
Number of subjects: 5623
Study: 22409922

Group type: EXPERIMENTAL
Intervention: Honghua Injection
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (routine Western medicine)
Number of subjects: 64
Study: 20409690

Group type: EXPERIMENTAL
Intervention: valsartan
Number of subjects: 1150

Group type: COMPARATOR
Intervention: amlodipine
Number of subjects: 1150
Study: 18841081

Group type: EXPERIMENTAL
Intervention: Static Stretching (SS)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Dynamic Stretching (DS)
Number of subjects: 51

Group type: COMPARATOR
Intervention: No Stretching (NS)
Number of subjects: 51
Study: 15969641

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 0.5% ophthalmic solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gatifloxacin 0.3% ophthalmic solution
Number of subjects: 0
Study: 14500440

Group type: EXPERIMENTAL
Intervention: System of structured asthma care (the 3+ visit plan)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 174
Study: 11910658

Group type: EXPERIMENTAL
Intervention: Alora
Number of subjects: 33

Group type: COMPARATOR
Intervention: Evorel
Number of subjects: 33
Study: 8695129

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg mivacurium (divided dose: 0.15 mg/kg followed by 0.1 mg/kg after 30 seconds)
Number of subjects: 200

Group type: COMPARATOR
Intervention: 1.5 mg/kg succinylcholine (preceded by 50 micrograms/kg d‐tubocurarine)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg mivacurium (divided dose)
Number of subjects: 200
Study: 1524174

Group type: EXPERIMENTAL
Intervention: Infiltration with 4.4 ml of 1:80,000 adrenaline and 2% lignocaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Moffett's solution containing 1 ml of 1:1,000 adrenaline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Infiltration group
Number of subjects: 20
Study: 6500458

Group type: EXPERIMENTAL
Intervention: Metered dose inhaler with small expander
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Metered dose inhaler with large expander
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Metered dose inhaler without expander
Number of subjects: 21
Study: 31420402

Group type: EXPERIMENTAL
Intervention: Thoracic epidural blockade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paravertebral blockade
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29457512

Group type: EXPERIMENTAL
Intervention: Perceived network exposure to daily sugar-sweetened beverages
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Perceived network exposure to daily sweets
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Perceived network exposure to weekly vigorous exercise
Number of subjects: 266

Group type: COMPARATOR
Intervention: Perceived network exposure to weekly moderate exercise
Number of subjects: 266
Study: 26680699

Group type: EXPERIMENTAL
Intervention: Strong African American Families (SAAF) program
Number of subjects: 399

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 399
Study: 24075236

Group type: EXPERIMENTAL
Intervention: Maxillomandibular fixation (MMF) screws
Number of subjects: 20

Group type: COMPARATOR
Intervention: Open reduction internal fixation (ORIF)
Number of subjects: 20
Study: 23123531

Group type: EXPERIMENTAL
Intervention: Hybrid treatment (4 weekly 2-hour sessions)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Monitoring Group (pain and sleep diary for 4 weeks)
Number of subjects: 20
Study: 20209697

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 microg every three hours, up to five doses)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Vaginal misoprostol (400 microg every three hours, up to five doses)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Vaginal misoprostol
Number of subjects: 50
Study: 18722968

Group type: EXPERIMENTAL
Intervention: 10 mL of 1% ropivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: 10 mL of sterile water
Number of subjects: 40
Study: 16038172

Group type: EXPERIMENTAL
Intervention: Prophylaxis with omeprazole 40 mg and metoclopramide 10 mg in group A
Number of subjects: 331

Group type: COMPARATOR
Intervention: Prophylaxis with omeprazole 40 mg and metoclopramide 10 mg in group B
Number of subjects: 331

Group type: COMPARATOR
Intervention: Prophylaxis with omeprazole 40 mg and metoclopramide 10 mg in group C
Number of subjects: 331

Group type: COMPARATOR
Intervention: No prophylaxis in group D
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Outpatient treatment for GERD in subgroup A1
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: No outpatient treatment for GERD in subgroup A2
Number of subjects: 331
Study: 12185449

Group type: EXPERIMENTAL
Intervention: Angiotensin I (30 ng kg(‐1) x min(‐1))
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: N-acetyl-Ser-Asp-Lys-Pro (AcSDKP; 1.12 micro g kg(‐1) x min(‐1))
Number of subjects: 24

Group type: COMPARATOR
Intervention: Captopril (inhibition of angiotensin I converting enzyme)
Number of subjects: 24
Study: 10561190

Group type: EXPERIMENTAL
Intervention: Pain intensity markers (3 types)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Pain relief scale
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Patient satisfaction scale
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Pain management indexes (3 types)
Number of subjects: 313
Study: 8684871

Group type: EXPERIMENTAL
Intervention: Brand trimethoprim‐sulfamethoxazole
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Brand and generic formulations of cephalexin and erythromycin‐sulfisoxazole
Number of subjects: 20

Group type: COMPARATOR
Intervention: Generic antibiotic suspensions
Number of subjects: 20
Study: 1725543

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 61

Group type: COMPARATOR
Intervention: Hydrochlorothiazide/Triamterene
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Diltiazem + Hydrochlorothiazide/Triamterene
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide/Triamterene + Diltiazem
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Diltiazem as first choice
Number of subjects: 61

Group type: COMPARATOR
Intervention: Hydrochlorothiazide/Triamterene alone
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide/Triamterene added to Diltiazem
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Diltiazem added to Hydrochlorothiazide/Triamterene
Number of subjects: 61
Study: 7080884

Group type: EXPERIMENTAL
Intervention: 16‐item Binge Eating Scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 11‐item Cognitive Factors Scale
Number of subjects: 0
Study: 29740842

Group type: EXPERIMENTAL
Intervention: Melatonin for 3 months
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 54
Study: 27414973

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care (PhC)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Standard nurse staff instructions (control)
Number of subjects: 128
Study: 23475701

Group type: EXPERIMENTAL
Intervention: Black race
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Higher PRA in nonblacks
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: PRA in blacks
Number of subjects: 323
Study: 23258574

Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 20804941

Group type: EXPERIMENTAL
Intervention: Intravenous alcohol administration
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 18060746

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250mg twice a day for 3 days
Number of subjects: 27

Group type: COMPARATOR
Intervention: Furagin 100mg three times a day for 7 days
Number of subjects: 27
Study: 16171664

Group type: EXPERIMENTAL
Intervention: 50 mg oral rofecoxib preoperatively with IV placebo injection
Number of subjects: 54

Group type: COMPARATOR
Intervention: 30 mg IV ketorolac preoperatively with placebo
Number of subjects: 54
Study: 12576891

Group type: EXPERIMENTAL
Intervention: Synchronous ligation with the new anoscope
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional ligation with a conventional anoscope
Number of subjects: 50
Study: 10573501

Group type: EXPERIMENTAL
Intervention: Dual chamber pacing (DDD)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Single chamber ventricular pacing (VVI)
Number of subjects: 12
Study: 11322256

Group type: EXPERIMENTAL
Intervention: Didanosine (500 mg daily or 750 mg daily depending on weight)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Zidovudine (600 mg daily)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Didanosine (low-dose)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Didanosine (high-dose)
Number of subjects: 356
Study: 1908745

Group type: EXPERIMENTAL
Intervention: Intramuscular Ig 25 mg/kg/wk
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Intramuscular Ig 50 mg/kg/wk
Number of subjects: 43

Group type: COMPARATOR
Intervention: Saline injections
Number of subjects: 43
Study: 6809420

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing IUDs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nova-T copper device
Number of subjects: 0
Study: 31842388

Group type: EXPERIMENTAL
Intervention: Stevia (1 g)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Water
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sugar (60 g)
Number of subjects: 30
Study: 30012318

Group type: EXPERIMENTAL
Intervention: NSAID use
Number of subjects: 18113
Study: 25824193

Group type: EXPERIMENTAL
Intervention: CT angiography (CTA)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Doppler ultrasound (US)
Number of subjects: 63
Study: 24165361

Group type: EXPERIMENTAL
Intervention: Maxillary osteotomy in CLP group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-cleft control group (NonCLP)
Number of subjects: 20
Study: 19825903

Group type: EXPERIMENTAL
Intervention: 300 mg pregabalin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 19700435

Group type: EXPERIMENTAL
Intervention: Infliximab treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-treatment colonic mucosal gene expression profiles
Number of subjects: 0
Study: 17005066

Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy (CST) combined with 5 mg of donepezil per day for one year.
Number of subjects: 30

Group type: COMPARATOR
Intervention: 5 mg of donepezil per day (control group).
Number of subjects: 30
Study: 15075418

Group type: EXPERIMENTAL
Intervention: Facility-based multiple-component training program followed by home-based adherence
Number of subjects: 150

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 150
Study: 11161371

Group type: EXPERIMENTAL
Intervention: Lumpectomy followed by radiotherapy (XRT group)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Lumpectomy alone (no-XRT group)
Number of subjects: 152
Study: 9448551

Group type: EXPERIMENTAL
Intervention: Improved glycemic control
Number of subjects: 0
Study: 8557061

Group type: EXPERIMENTAL
Intervention: Cholestyramine (4 g with a liquid meal)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Cholestyramine (4 g every 2 days for 1 month)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Liquid meal (two egg yolks plus water 200 mL, 50 kJ)
Number of subjects: 27
Study: 1973768

Group type: EXPERIMENTAL
Intervention: L-thyroxine (T4, 2.5 micrograms/kg body weight daily)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: L-thyroxine (T4, 2.5 micrograms/kg body weight daily) + carbimazole (CBZ, 40 mg daily)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 924705

Group type: EXPERIMENTAL
Intervention: solufenum
Number of subjects: 5

Group type: COMPARATOR
Intervention: ibuprofen
Number of subjects: 5
Study: 30281552

Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral corticosteroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Willingness to enroll in RCT
Number of subjects: 0
Study: 31490964

Group type: EXPERIMENTAL
Intervention: Intensive social marketing intervention
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no intensive intervention)
Number of subjects: 10
Study: 26242287

Group type: EXPERIMENTAL
Intervention: Acupressure at UB60 and K3 points for 3 minutes before heel prick
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no acupressure)
Number of subjects: 32
Study: 23753039

Group type: EXPERIMENTAL
Intervention: Peer-patient navigation
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Pro-patient navigation
Number of subjects: 350

Group type: COMPARATOR
Intervention: Standard navigation
Number of subjects: 350
Study: 22208800

Group type: EXPERIMENTAL
Intervention: Implementation strategy (including training session, information distribution, opinion leader) of a breastfeeding guideline in primary care
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual diffusion
Number of subjects: 240
Study: 19114187

Group type: EXPERIMENTAL
Intervention: Reconstituted fresh whole blood
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard blood component therapy
Number of subjects: 64
Study: 16571129

Group type: EXPERIMENTAL
Intervention: Flexitouch
Number of subjects: 10

Group type: COMPARATOR
Intervention: Massage
Number of subjects: 10

Group type: COMPARATOR
Intervention: Flexitouch and Massage
Number of subjects: 10